Tisagenlecleucel (Kymriah) will be available for certain leukemia patients through the Cancer Drugs Fund.
Medicare officials are expected to make a national coverage decision on CAR T-cell therapies in February 2019.
The “slower burning” 4-1BB CAR signal led to T cells that better retained their function in vivo and were associated with longer median survival...
Medical associations are disappointed with CMS’s payment structure for CAR T-cell therapy usage, calling it insufficient.
From the Journals
“It seems reasonable to envision a day when gene therapy will be a mainstay of treatment for many diseases,” Dr. Collins and Dr. Gottlieb wrote....
Physicians may finally have some payment clarity for inpatient administration of two CAR T-cell therapies.
NEWPORT BEACH, CALIF. – A revised HCT-CI for adolescents and young adults is useful for predicting nonrelapse mortality in this specific...
SALT LAKE CITY – The presence of p2X7 SNPs could be incorporated into disease risk models to improve transplant decision making.
SALT LAKE CITY – Pre-allogeneic HCT assessment of functional status and endurance provides important insights into posttransplant outcomes.
SALT LAKE CITY – Normal puberty does not equate to normal fertility, researchers found.